Filters
Sort by
Physical Rehabilitation in Adults With Sickle Cell Anemia: Effects on Muscle Function, Functional Capacity and Quality of Life

Sickle cell anemia (SCA) is one of the most neglected diseases worldwide, according to the World Health Organization.

Locations

1 Brazil site

Age

18 to 60 Years

Phase

N/A

LEARN MORE
A Test of the Safety, Effectiveness, and Acceptability of an Improvised Dressing for Sickle Cell Leg Ulcers in a Tropical Climate

One in 300 Jamaicans have HbSS sickle cell disease, and of these, up to 70% will suffer from sickle cell leg ulcers (SCLUs).

Locations

1 Jamaica site

Age

13 to 70 Years

Genotypes

HbSS

Phase

N/A

LEARN MORE
Low Dose Ketamine for Acute Pain Crisis in Patients With Sickle Cell Disease

BACKGROUND: Current treatment standard for acute pain crisis in sickle cell disease (SCD) is largely supportive care: opioid analgesics, hydration, oxygen, and blood transfusion.

Locations

2 United States sites

Age

> 18 Years

Phase

Phase 4

LEARN MORE
Evaluation of Vitamin D Deficiency Distribution in Children With Sickle Cell Disease Followed in Lyon, France

Vitamin D deficiency may be under-diagnosed in sickle cell disease French children.

Locations

1 France site

Age

< 17 Years

LEARN MORE
Designing an Implementation Strategy for Delivering Routine Mental Health Screening and Treatment for Adolescents and Adults With Sickle Cell Disease

African Americans living with chronic health conditions are more likely to experience depression and other mental health disorders than their healthy counterparts, and are more likely to experience severe depression than whites, but less likely to be diagnosed or receive treatment.

Locations

1 United States site

Age

16 to 30 Years

Phase

N/A

LEARN MORE
Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

Background: Sickle cell disease (SCD) is an inherited blood disorder.

Locations

1 United States site

Age

18 to 99 Years

Genotypes

HbSS

Phase

Early Phase 1

LEARN MORE
SMYLS: A Self-management Program for Youth Living With Sickle Cell Disease

The purpose of this study is to find out whether a web-based intervention using a mobile device is helpful for teens learning to care for and manage symptoms of sickle cell disease.

Locations

1 United States site

Age

11 to 17 Years

Phase

N/A

LEARN MORE
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

This is a multi-center, long-term safety and efficacy follow-up study for subjects with sickle cell disease who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies.

Locations

2 United States sites

1 France site

Age

2 to 53 Years

LEARN MORE
Obesity in Pediatric Sickle Cell Disease: A New Phenomenon

The objective of this project is to determine the prevalence of hypertension, hyperlipidemia and hyperglycemia in the pediatric population with sickle cell disease who are obese in Mississippi compared to those pediatric patients with sickle cell disease who are not overweight/obese.

Age

10 to 19 Years

Genotypes

HbSS, HbSC

LEARN MORE
A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients With Sickle Cell Disease

This is a dose escalation study to evaluate the safety and tolerability of voxelotor at daily doses of 1500 mg to 3000 mg in participants with sickle cell disease (SCD).

Locations

6 United Kingdom sites

Age

18 to 60 Years

Genotypes

HbSS

Phase

Phase 2

LEARN MORE
Site is under construction